First Platform for Massively Multiplexed Single-Cell In Situ Spatial Genomics Now Broadly Available to U.S. Market
Retrieved on:
星期二, 一月 18, 2022
Science, Other Science, Research, Research, Technology, Actinin alpha 3, LinkedIn, Liver, Biology, Translational Genomics Research Institute, Genomics, Emerging technologies, Nutrient, Old, Science, Gene, CEO, Social media, Allen Institute for Brain Science, Hepatocyte, Â, Oxygen, Disease, Center, Health, Regenerative medicine, Map, DAPI, Tissue, Infection, Efficiency, Associate, CYP1A2, Allen Institute, Multimedia, Neuroscience, Developmental biology, Twitter, Cell, Brain, Allen, Drug discovery, Data visualization, Medical imaging, Microscope, Facebook, the Data Release Program at Vizgen, the Interactive Web Visualizer, Vizgen, THE DATA RELEASE PROGRAM AT VIZGEN, THE INTERACTIVE WEB VISUALIZER, VIZGEN
(Photo: Business Wire)
Key Points:
- (Photo: Business Wire)
Through MERSCOPE, a one-of-a-kind single-cell spatial genomics platform technology, Vizgen is ushering in a new era in genomics. - We are working with our customers to bring new platform capabilities and applications throughout the year and continue to lead this new era of spatial genomics.
- Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field.
- The company's MERSCOPETM Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution.